FDA Grants Fast Track Status to KYV-101 for Refractory Lupus Nephritis Treatment
Kyverna Therapeutics announced that the FDA has given Fast Track status to KYV-101, a treatment for patients suffering from resistant lupus nephritis (LN). KYV-101 is an innovative therapy that uses anti-CD19 chimeric antigen receptor T-cells (CAR T) to eliminate B cells, including those that are self-reactive, in individuals with autoimmune diseases.
Peter Maag, Ph.D., CEO of Kyverna, expressed his enthusiasm about the FDA granting Fast Track designation for KYV-101. This designation enables the company to expedite the process of making this potentially groundbreaking and life-savi...
